Rapid communication
Endogenous nitric oxide counteracts antigen-induced bronchoconstriction

https://doi.org/10.1016/0014-2999(93)90532-MGet rights and content

Abstract

In anesthetized, artificially ventilated guinea pigs immunized against ovalbumin, challenge with aerosolized ovalbumin (0.1 mg) elicited a substantial and sustained increase of insufflation pressure. The inhibitor of endogenous nitric oxide (NO) synthesis, L-NAME (Nω-nitro-L-arginine methylester, 30 mg kg−1 i.v.), markedly augmented the response, the potentiation of which could be prevented by NO (20 p.p.m.) in the inhaled air. The results indicate an inhibitory effect of endogenous NO on antigen-induced bronchoconstriction.

References (5)

There are more references available in the full text version of this article.

Cited by (45)

  • Production of nitric oxide by airways neutrophils in the initial phase of murine asthma

    2007, International Immunopharmacology
    Citation Excerpt :

    We have recently shown [18] that inhibition of NOS2 by l-NAME reduced airway hyperreactivity and eosinophil infiltration in allergic lung inflammation in mice suggesting that NO has a pro-inflammatory effect. Similar studies in guinea pigs have shown that NOS inhibitors potentiated acute bronchoconstriction induced by allergen inhalation [32,33], whereas other studies in vitro and in vivo showed that the hyperreactivity induced by allergens is not affected by pretreatment with NOS inhibitors [33,34]. These discrepant results could be attributed to the different models employed but also to the phase of the allergic inflammation analyzed.

  • Acute inhibition of inducible nitric oxide synthase but not its absence suppresses asthma-like responses

    2005, European Journal of Pharmacology
    Citation Excerpt :

    Actually, the role of nitric oxide in the airway hyperreactivity is controversial (Ricciardolo et al., 1997; Ricciardolo, 2003; Keller et al., 2005). Some studies in guinea pigs have shown NOS inhibitors potentiate acute bronchoconstriction induced by allergen inhalation (Persson et al., 1993; Mehta et al., 1997), whereas other studies in vitro and in vivo showed that the hyperreactivity induced by allergen is not affected by pre-treatment with NOS inhibitors (de Boer et al., 1996; Mehta et al., 1997). In a recent clinical study, NOS2 inhibitors were able to decrease the exhaled nitric oxide levels in asthmatics patients but the benefit of this treatment on clinical symptoms was not reported (Hansel et al., 2003).

  • Nitric oxide in respiratory diseases

    2002, Pharmacology and Therapeutics
  • Measurement of exhaled nitric oxide in humans and animals

    1999, Pulmonary Pharmacology and Therapeutics
View all citing articles on Scopus
View full text